This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan
Arthritis Research & Therapy Open Access 22 January 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Charles C, Clements P, Furst DE . Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006; 367: 1683–1691.
Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655–2666.
Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809–1815.
Bryan C, Knight C, Black CM, Silman AJ . Prediction of five-year survival following presentation with scleroderma—development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42: 2660–2665.
Tyndall A, Gratwohl A . Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 643–645.
Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010; 95: 284–292.
van Laar JM, Farge D, Tyndall A . Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis 2005; 64: 1515.
Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen C-S, Godwin JD et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007; 110: 1388–1396.
Snowden JA, Biggs JC, Milliken ST, Fuller A, Brooks PM . A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthritis Rheum 1999; 42: 2286–2292.
Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498–506.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Moore, J., Englert, H., Furlong, T. et al. Auto-HSCT induces sustained responses in severe systemic sclerosis patients failing pulse cyclophosphamide. Bone Marrow Transplant 47, 1486–1487 (2012). https://doi.org/10.1038/bmt.2012.67
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.67